Evotec SE

Evotec SE focuses on drug discovery, preclinical development, and manufacturing for the pharmaceutical and biotechnology industry. The company provides partners with access to its platforms across the continuum of discovery, development, and manufacturing. As of December 31, 2025, Evotec had a workforce of 3,682 scientific experts. The company's expertise spans oncology, central nervous system (CNS) disorders, cardiovascular-renal (CVRM) disorders, immune & inflammatory (I&I) and infectious diseases, fibrotic and respiratory diseases, women's health, rare diseases, and animal health. Evotec's strategy emphasizes technology and science leadership, particularly in AI-driven innovation, molecular glue degraders, and targeted protein degradation. The company utilizes proprietary technologies and platforms, including molecular patient databases, induced pluripotent stem-cell based disease modeling, high-performance Omics technologies, and integrated platforms for drug screening, profiling, development, and manufacturing. Evotec offers customized, results-focused partnerships, which can be based on standalone and/or integrated fee-for-service relationships. Additionally, Evotec forms strategic partnerships to co-create pipelines using proprietary assets, targets, or technology platforms.